All In Biotech

Drug Trial Radar · NCT00491829

Flibanserin Versus Placebo in Premenopausal Women With HSDD

A Twenty-Four Week, Randomized, Double-Blind, Placebo Controlled, Safety and Efficacy Trial of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in Premenopausal European Women With Hypoactive Sexual Desire Disorder

Last checked: Nov 20, 2026Latest source record: Jun 2, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 945 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

945

Actual

Start

Jun 2007

Primary completion

Mar 2009

Study completion Mar 2009

Sponsor

Lead sponsor
Sprout Pharmaceuticals, IncIndustry
Sponsor type
Industry
First posted
Jun 26, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To establish efficacy of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in 6-month treatment, vs placebo for Hypoactive Sexual Desire Disorder in premenopausal European women. To evaluate safety and tolerability of flibanserin in such patients.

Conditions

  • Sexual Dysfunctions, Psychological

Interventions

  • 50 mg qhsDrug

    flibanserin 50 mg

  • 100 mgDrug

    flibanserin 100mg

  • placeboDrug

    placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Frequency of Satisfying Sexual Events as Measured by the eDiary.Time frame: baseline to 24 weeks

Locations

86 sites in 13 countries. Site status is shown where the registry gives one.

  • 511.77.43005 Boehringer Ingelheim Investigational Site

    Innsbruck, Austria

  • 511.77.43001 Boehringer Ingelheim Investigational Site

    Vienna, Austria

  • 511.77.43002 Boehringer Ingelheim Investigational Site

    Vienna, Austria

  • 511.77.43004 Boehringer Ingelheim Investigational Site

    Vienna, Austria

  • 511.77.43006 Boehringer Ingelheim Investigational Site

    Wörgl, Austria

  • 511.77.32004 Boehringer Ingelheim Investigational Site

    Braine-l'Alleud, Belgium

  • 511.77.32003 Boehringer Ingelheim Investigational Site

    Edegem, Belgium

  • 511.77.32005 Boehringer Ingelheim Investigational Site

    Ghent, Belgium

  • 511.77.32006 Boehringer Ingelheim Investigational Site

    Hasselt, Belgium

  • 511.77.32002 Boehringer Ingelheim Investigational Site

    Yvoir, Belgium

  • 511.77.42001 Boehringer Ingelheim Investigational Site

    Olomouc, Czechia

  • 511.77.42002 Boehringer Ingelheim Investigational Site

    Prague, Czechia

  • 511.77.42003 Boehringer Ingelheim Investigational Site

    Prague, Czechia

  • 511.77.42004 Boehringer Ingelheim Investigational Site

    Vřesina, Czechia

  • 511.77.35801 Boehringer Ingelheim Investigational Site

    Espoo, Finland

  • 511.77.35805 Boehringer Ingelheim Investigational Site

    Helsinki, Finland

  • 511.77.35802 Boehringer Ingelheim Investigational Site

    Oulu, Finland

  • 511.77.35803 Boehringer Ingelheim Investigational Site

    Seinäjoki, Finland

  • 511.77.35804 Boehringer Ingelheim Investigational Site

    Tampere, Finland

  • 511.77.3308A Boehringer Ingelheim Investigational Site

    Blanquefort, France

  • 511.77.3301A Boehringer Ingelheim Investigational Site

    Bordeaux, France

  • 511.77.3305A Boehringer Ingelheim Investigational Site

    La Rochelle, France

  • 511.77.3314A Boehringer Ingelheim Investigational Site

    Lille, France

  • 511.77.3314B Cabinet médical

    Lille, France

  • 511.77.3314C Cabinet médical

    Lille, France

  • 511.77.3303A Boehringer Ingelheim Investigational Site

    Marseille, France

  • 511.77.3310A Boehringer Ingelheim Investigational Site

    Marseille, France

  • 511.77.3312A Boehringer Ingelheim Investigational Site

    Marseille, France

  • 511.77.3302A Boehringer Ingelheim Investigational Site

    Paris, France

  • 511.77.3315A Cabinet Médical

    Rennes, France

  • 511.77.3306A Boehringer Ingelheim Investigational Site

    Saint-Émilion, France

  • 511.77.3311A Boehringer Ingelheim Investigational Site

    Toulouse, France

  • 511.77.49004 Boehringer Ingelheim Investigational Site

    Berlin, Germany

  • 511.77.49007 Boehringer Ingelheim Investigational Site

    Bochum, Germany

  • 511.77.49001 Boehringer Ingelheim Investigational Site

    Bonn, Germany

  • 511.77.49006 Boehringer Ingelheim Investigational Site

    Dresden, Germany

  • 511.77.49008 Boehringer Ingelheim Investigational Site

    Frankfurt, Germany

  • 511.77.49003 Boehringer Ingelheim Investigational Site

    Freiburg im Breisgau, Germany

  • 511.77.49002 Boehringer Ingelheim Investigational Site

    Hanover, Germany

  • 511.77.49005 Boehringer Ingelheim Investigational Site

    Leipzig, Germany

Showing 40 of 86 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.